FBXW5

Across TCGA pan-cancer cohorts, FBXW5 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated FBXW5 data layer compared with 30 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FBXW5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXW5 expression acts as an unfavorable survival marker.

LIHC, CESC, and COAD are the cancer types where FBXW5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.059	0.772	<.001	30	view →
CESC	OS	Median	II,III,IV	0.167	0.759	.010	18	view →
COAD	OS	Median	All	0.158	0.674	.006	10	view →
TGCT	DFS	Median	All	0.172	0.801	.033	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	III,IV	0.159	0.572	.036	3	view →
SKCM	OS	Median	All	0.233	0.786	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

FBXW5–LIHC (OS)

Open the LIHC breakdown →